Previous 10 | Next 10 |
Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event on m uscle r egeneration f...
HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI) , a leading biotechnology company, today announced that it has received approval for an additional grant from the Israel Innovation Authority (IIA) to support...
Enlivex Therapeutics ENLV +22% to launch Phase IIb Allocetra trial for COVID-19 patients in Israel ADMA Biologics ADMA +17% on FDA approval for plasma collection facility in Maryville, TN Travere Therapeutics TVTX +17% meets primary efficacy endpoint in late-stag...
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine...
Pluristem Therapeutics (PSTI) announces that it is bringing its Acute Respiratory Distress Syndrome ((ARDS)) associated with COVID-19 Phase II studies to clinical readout.The analysis will be based on 89 patients enrolled in two Phase II studies, which investigated the safety and efficacy of ...
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel Topline results are expected during the fourth quarter of 2021 HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ...
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...
AnPac Bio-Medical Science (ANPC) +29% on launching novel Cancer treatment technology and product JV.Pieris Pharmaceuticals (PIRS) +21% on collaboration with Genentech.Ault Global Holdings (DPW) +14% on Q1 results.Taiwan Liposome Company (TLC) +13% as its application for Am...
News, Short Squeeze, Breakout and More Instantly...
Pluristem Therapeutics Inc. Company Name:
PSTI Stock Symbol:
NASDAQ Market:
Pluristem Therapeutics Inc. Website:
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”) (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executi...
As of July 26 , 2022 , Pluri ’s stock will trade under the symbol PLUR The new name reflects the Company ’s strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cel...
The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m. ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA HAIFA, Israel, Ju...